Skip to main content
Clinical Trials/IRCT20190514043586N1
IRCT20190514043586N1
Completed
Phase 3

comparison of the efficacy and complication of two medication regimen 'naproxen and loratadin’ with 'acetaminophen and loratadin' on relief of bone pain due to PEG G-csf in patients with solid tumors chemotherapy

Shahid Beheshti University of Medical Sciences0 sites200 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Shahid Beheshti University of Medical Sciences
Enrollment
200
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • People with Solid Tumor or Lymphoma who receive PEG G\-CSF due to neutropenia after chemotherapy

Exclusion Criteria

  • Bone matastasis
  • PFS more than 2
  • Osteomalacia proven with laboratory tests
  • CKD or ESRD
  • Active Rheumatologic disease
  • Uncontrolled Diabetes or Thyroid disease
  • Patients receiving chemotherapy drugs that have bone pain are a high prevalence of 10% (TAXAN family, bisphosphonate ...)
  • Pathologic fracture or fracture due to any reason
  • Naproxen use contraindication
  • Vitamin D level less than 20

Outcomes

Primary Outcomes

Not specified

Similar Trials